201 related articles for article (PubMed ID: 12068339)
1. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.
Chapman KR; Arvidsson P; Chuchalin AG; Dhillon DP; Faurschou P; Goldstein RS; Kuipers AF;
Can Respir J; 2002; 9(3):178-85. PubMed ID: 12068339
[TBL] [Abstract][Full Text] [Related]
2. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
4. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline.
Dal Negro RW; Pomari C; Tognella S; Micheletto C
Pulm Pharmacol Ther; 2003; 16(4):241-6. PubMed ID: 12850128
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
6. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
Baloira Villar A; Vilariño Pombo C
Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
Hanania NA; Darken P; Horstman D; Reisner C; Lee B; Davis S; Shah T
Chest; 2003 Sep; 124(3):834-43. PubMed ID: 12970006
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.
Hodder R; Kesten S; Menjoge S; Viel K
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):157-67. PubMed ID: 18044688
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
Rabe KF; Timmer W; Sagkriotis A; Viel K
Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
[TBL] [Abstract][Full Text] [Related]
10. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
Cote C; Pearle JL; Sharafkhaneh A; Spangenthal S
Pulm Pharmacol Ther; 2009 Feb; 22(1):44-9. PubMed ID: 19071226
[TBL] [Abstract][Full Text] [Related]
11. Salmeterol plus theophylline combination therapy in the treatment of COPD.
ZuWallack RL; Mahler DA; Reilly D; Church N; Emmett A; Rickard K; Knobil K
Chest; 2001 Jun; 119(6):1661-70. PubMed ID: 11399688
[TBL] [Abstract][Full Text] [Related]
12. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
13. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of salmeterol and fluticasone or theophylline in COPD.
Cazzola M; Di Lorenzo G; Di Perna F; Calderaro F; Testi R; Centanni S
Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
[TBL] [Abstract][Full Text] [Related]
16. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.
Donohue JF; van Noord JA; Bateman ED; Langley SJ; Lee A; Witek TJ; Kesten S; Towse L
Chest; 2002 Jul; 122(1):47-55. PubMed ID: 12114338
[TBL] [Abstract][Full Text] [Related]
17. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of salmeterol xinafoate in the treatment of COPD.
Mahler DA; Donohue JF; Barbee RA; Goldman MD; Gross NJ; Wisniewski ME; Yancey SW; Zakes BA; Rickard KA; Anderson WH
Chest; 1999 Apr; 115(4):957-65. PubMed ID: 10208192
[TBL] [Abstract][Full Text] [Related]
20. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
